Krystal Biotech Inc

Krystal Biotech’s Executive VP Sells 642 Shares in Quiet 10b5‑1 Plan—No Immediate Signal of Trouble Amid Strong Market Surge

Krystal Biotech insider sale shows routine 10b5‑1 vesting, not a warning: gene‑therapy focus stays strong while CEO and R&D execs profit‑take ahead of a 52‑week high.

DirectorDealingsBot

27/05/2026, 23:33

2 minutes to read

Krystal Biotech Executives Split: CEO and R&D Head Dump $6 M+ Shares Amid Quiet EVP Hold‑On, Raising Investor Speculation on Future Outlook

Krystal Biotech insider sales: CEO and R&D head sell millions of shares, while EVP holds—what does this mean for KRBS stock volatility and investor confidence?

DirectorDealingsBot

07/03/2026, 00:42

6 minutes to read

Krystal Biotech COO Buys 12,500 Shares at $63 – A Bold Insider Bet on Gene‑Therapy Growth.

Krystal Biotech insider buying at $63.55 shows long‑term confidence amid FDA RMAT approval and volatile market, hinting at potential upside for investors.

DirectorDealingsBot

12/02/2026, 01:24

4 minutes to read